Follow us on Twitter
twitter icon@FreshPatents

Autoimmune patents

Bulk PDF Downloads
      

This page is updated frequently with new Autoimmune-related patent applications.




 Method of producing fr901228 patent thumbnailnew patent Method of producing fr901228
Depsipeptides and congeners thereof are disclosed having structure (i), wherein m, n, p, q, x, r1, r2 and r3 are as defined herein. These compounds, including fr901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant.
Astellas Pharma Inc.


 Anti-kir antibodies patent thumbnailnew patent Anti-kir antibodies
Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (kir)-targeting agents) that target a subset of t lymphocytes present in disease states (e.g., lupus and other autoimmune diseases) and methods of treating conditions and/or diseases therewith. In particular, anti-kir antibodies, fragments thereof, or related compositions are provided for the treatment of conditions and/or diseases (e.g., lupus and other autoimmune diseases, atherosclerosis, etc.)..
The Regents Of The University Of Michigan


 Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses patent thumbnailnew patent Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses
The novel positively charged pro-drugs of nsaias in the general formulas (1, 2a, 2b, 2c, or 2d) “structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of nsaias with suitable halide compounds.
Techfields Pharma Co., Ltd.


 Compositions and methods for the prevention and treatment of autoimmune conditions patent thumbnailnew patent Compositions and methods for the prevention and treatment of autoimmune conditions
The methods include selectively reducing or expanding t cells according to the antigenic specificity of the t cells. Therefore, the present invention can be used to reduce or eliminate pathogenic t cells that recognize autoantigens, such as beta cell specific t cells.
Uti Limited Partnership


 Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans patent thumbnailnew patent Methods of treating allergies and autoimmune diseases with homogenate of axenic c. elegans
Methods of using axenic c. Elegans homogenate for treating allergies or an autoimmune disease are disclosed.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


 Modulators of syndecan-2 and uses thereof patent thumbnailnew patent Modulators of syndecan-2 and uses thereof
Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndiecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a th17 mediated disease such as an autoimmune disease, fibrosis or cancer.. .
Orbsen Therapeutics Limited


 Il-17 production inhibitory composition patent thumbnailnew patent Il-17 production inhibitory composition
Provided is a composition for preventing or treating il-17-related diseases, more specifically, autoimmune diseases and inflammatory diseases induced by an increase of il-17. The il-17 production inhibitory composition is characterized by containing mesenchymal stem cells originated from an adipose tissue as an active ingredient.
Anterogen Co., Ltd.


 Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives patent thumbnailnew patent Polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives
The present invention provides compounds represented by formula (i) and pharmaceutical acceptable salts thereof, preparation method therefor and pharmaceutical composition containing the compounds represented by formula (i) and pharmaceutical acceptable salts thereof. In the compounds of the present invention, each terminal group of polyethylene glycol molecule can bond with a plurality of rapamycin molecules by cactus oligopeptide, with the loading rate of the pharmaceutical being increased.
Jenkem Technology Co., Ltd.


 Biological markers and methods for predicting response to b-cell antagonists patent thumbnailBiological markers and methods for predicting response to b-cell antagonists
Biological markers that predict patient responsiveness to b-cell antagonists are provided. Also provided are methods of using such biological markers.
Genentech, Inc.


 Methods of reducing serum levels of fc-containing agents using fcrn antagonists patent thumbnailMethods of reducing serum levels of fc-containing agents using fcrn antagonists
Provided are novel methods of reducing the serum levels of fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated fcrn-antagonist that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region.
Argen-x N.v.


Il-3 blockade in systemic lupus erythematosus and multiple sclerosis


The present invention relates to anti-il-3 antibodies or il-3 binding fragments thereof for use in the treatment of an autoimmune disease selected from the group consisting of systemic lupus erythematosus and multiple sclerosis, and to pharmaceutical compositions comprising such an antibody or antibody fragment.. .
UniversitÄtsklinikum Regensburg


Novel scorpion toxin analogue and treating autoimmune diseases


A novel peptide analogue of the heterometrus spinnifer toxin hstx1 is disclosed along with its application as, for example, a therapeutic agent for treating an autoimmune disease such as multiple sclerosis (ms) or rheumatoid arthritis (ra). The analogue comprises a peptide with an amino acid substitution at amino acid position 14 of the wild-type (wt) peptide sequence (or a position corresponding to position 14 of the wt peptide sequence).
Baylor College Of Medicine


Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


Heteromaromatic compounds useful for the treatment of prolferative diseases


The present invention provides novel compounds of formula (i) and formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.


Heteroaromatic compounds useful for the treatment of prolferative diseases


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


Cell, tissue and organ protection using a magnetic field


Methods and apparatus are provided for applying low magnetic fields (<400 g) to mammalian cells, tissues and organs for protection from the damaging effects of ionizing radiation and other oxygen dependent injuries that involve the radical pair mechanism. The magnetic fields are generated by fixed magnets or active magnets and used to enhance the survival of healthy cells during radiation treatment for cancer, to protect workers from radiation within nuclear power plants, to protect astronauts from radiation during long space voyages, to increase working time in exposed environments, to provide a safe room in hazardous locations, and to protect normal tissue during radiation treatment and in medical imaging modalities that use ionizing radiation (x-ray, ct, mammography).
The Trustees Of The University Of Pennsylvania


Phytochemical compositions and techniques for immunomodulation, including anti-pathogen and anti-autoimmune-disorder immunomodulation


A phytochemical anti-pathogen/anti-cancer composition is provided that includes an extract of mangosteen; an extract of defatted soybean; an extract of gotu kola; and optionally an extract of black sesame, where an amount of the extract of black sesame is controlled relative to an amount of the extract of gotu kola, or an amount of a combination of the extract of rriangosteen, the extract of defatted soybean, and the extract of gotu kola, in order to preferentially support antipathogen/anti-cancer immunomodulatoty effects. A phytochemical anti-autoimmune disorder composition containing the same four ingredients, where an amount of the extract of gotu kola is controlled relative to the amounts of the other extracts is also provided.
Asian Phytoceuticals Public Company Limited


Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders


The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases.
Case Western Reserve University


Her2/neu-specific antibodies and methods of using same


This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Selective inhibitors of proteinase 3


The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the invention concerns nov peptidyl phosphonate esters compounds, including without limitation, compounds with asp-tyr-asp-ala or pro-tyr-asp-ala, pro-tyr-asp-avl, val-tyr-asp-avl peptide structure or their derivatives..
Uniwersytet Gdanski


Purinone derivatives as tyrosine kinase inhibitors


The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular blk, bmx, egfr, her2, her4, itk, tec, btk, and txk and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof..
Principia Biopharma Inc.


New 1-(4-pyrimidinyl)-1h-pyrrolo[3,2-c]pyridine derivatives as nik inhibitors


The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of nf-κb-inducing kinase (nik—also known as map3k14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders..
Janssen Pharmaceutica Nv


Thiadiazolidinediones as gsk-3 inhibitors


The present invention relates to new thiadiazolidinediones of formula (i), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (gsk-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them..
Asd Therapeutics Partners Llc


Benzazepine dicarboxamide compounds


Wherein r1 to r4 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are tlr agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases..

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation..

Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor


Described herein are pharmaceutical formulations of bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics Llc


Diagnosis and treatment of autoimmune diseases


Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, crohn's disease, and ulcerative colitis.. .
Dyax Corp.


Monitoring health and disease status using clonotype profiles


There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.


Therapeutic use of anti-cd22 antibodies for inducing trogocytosis


Disclosed are methods and compositions of anti-b cell antibodies, preferably anti-cd22 antibodies, for diagnosis, prognosis and therapy of b-cell associated diseases, such as b-cell malignancies, autoimmune disease and immune dysfunction disease. Preferably, the antibodies induce trogocytosis of b-cell antigens, such as cd19, cd20, cd21, cd22, cd79b, cd44, cd62l, or β7-integrin.
Immunomedics, Inc.


Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof


Novel activating receptors of the lg super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s


Chromene derivatives as inhibitors of tcr-nck interaction


And which present the ability to inhibit the lymphocytes proliferation mediated by the tcr interaction with nck, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions wherein said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.. .

Carboxylic acid compounds


The present disclosure concerns at least one entity chosen from compounds of formula (i) and pharmaceutically acceptable salts thereof: (i) wherein the variable groups x, r1, r2, r3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer..
Astrazeneca Aktiebolag


Bicyclic compounds


And/or a salt thereof; wherein r is —oh or —op(o)(oh)2. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as immunostimulating agent/adjuvant


The present invention relates to nucleic acids of the general formula (i): (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (i) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g.
Curevac Ag


Methods for induction of antigen-specific regulatory t cells


The present invention relates to methods of obtaining antigen-specific regulatory cells in vitro or in vivo. The regulatory cells are obtainable by inducing apoptosis of antigen-presenting cells by nkt cells.
Imcyse Sa


Treating organ-specific t cell mediated autoimmune diseases


The specification provides methods of treating a subject with an organ-specific t cell mediated autoimmune disease.. .
University Of Massachusetts


Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease.
Biosuccess Biotech Co. Ltd.


Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same


Methods of identifying a subject having an autoimmune disease, such as type 1 diabetes, as likely to respond to treatment with a tumor necrosis factor-alpha (tnf-α) receptor ii activator, involving measuring cd8 protein density on the surface of autoreactive cd8+ t cells and identifying the subject as likely to respond to the treatment if the cd8 protein density is reduced relative to a reference cd8+ t cell. For type 1 diabetes, the method may involve measuring c-peptide levels in an in vitro biological sample from the subject, identifying the subject as likely to respond to the treatment if the c-peptide levels are detectable, and identifying the subject as unlikely to respond to the treatment if the c-peptide levels are substantially undetectable.
The General Hospital Corporation




Autoimmune topics:
  • Autoimmune
  • Immune Disease
  • Autoimmune Disease
  • Immune Diseases
  • Autoimmune Diseases
  • Transplant
  • Immune Disorder
  • Autoimmune Disorder
  • Autoimmune Disorders
  • Infectious
  • Infectious Disease
  • Inflammatory Disease
  • Type 1 Diabetes
  • Proliferative Disorder
  • Recurrence


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.5281

    5238

    0 - 1 - 102